Loading...
XSHE
300255
Market cap2.97bUSD
Jul 10, Last price  
26.34CNY
1D
20.00%
1Q
-35.85%
Jan 2017
233.42%
IPO
530.14%
Name

Hebei Changshan Biochemical Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300255 chart
P/E
P/S
27.66
EPS
Div Yield, %
Shrs. gr., 5y
-0.03%
Rev. gr., 5y
-18.02%
Revenues
875m
-15.10%
110,840,402253,753,457466,717,967423,479,330572,499,692704,542,401811,284,569915,987,2291,118,414,4301,420,161,4481,652,633,9202,071,479,8092,363,785,8542,968,050,8422,336,229,8371,410,439,6481,030,810,532875,132,346
Net income
-358m
L+43.46%
9,283,26936,365,48660,190,52670,799,65699,088,101115,182,923133,732,533156,297,279175,487,229196,919,216139,987,097225,285,380252,842,319233,573,84417,513,467-1,240,210,952-249,477,721-357,895,551
CFO
56m
-0.95%
-30,826,60424,210,52129,245,67417,041,533-70,620,873-15,244,396-84,967,293-38,139,133171,959,738162,275,728292,806,829-58,127,157-183,581,1742,871,4983,125,50333,725,97956,218,17055,682,878
Dividend
Jun 27, 20230.005 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. operates within China, focusing on the entire lifecycle of heparin-based pharmaceuticals – from their initial research and development to manufacturing and sales. Their products are primarily utilized for the treatment of cardiovascular and cerebrovascular diseases. The company offers a broad range of heparin compounds, including crude heparin sodium and refined heparin sodium raw materials. Their portfolio also features a variety of injectable heparin preparations, such as standard heparin sodium injections. Furthermore, they produce both the raw materials and finished injectable forms for several low molecular weight heparins, specifically low molecular weight heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium. Established in the year 2000, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is headquartered in Shijiazhuang, China.
IPO date
Aug 19, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT